Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study Assessing the BET-bromodomain (BRD) Inhibitor OTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)

NCT02303782 is registered in ClinicalTrials.gov with Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) as lead sponsor.

NCT NCT02303782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02303782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study Assessing the BET-bromodomain (BRD) Inhibitor OTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)
Lead sponsor
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase
Phase 1/2
Overall status
Withdrawn
Start date
January 31, 2015
Completion date
March 31, 2016
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia